Clinical Trial Update: A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial for a 12-month treatment in C3 glomerulopathy-related conditions (C3 Glomerulonephritis/IC-MPGN) with ACH-0144471 was terminated;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulonephritis
• C3 Glomerulopathy
• Dense Deposit Disease
• Ic-mpgn
• Immune Complex Membranoproliferative Glomerulonephritis

Drugs mentioned

• ACH-0144471

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: C3 Glomerulonephritis, C3 Glomerulopathy | Phase 2 | Status: TERMINATED | Results posted: 2022-08-11